Syed covers the Healthcare sector, focusing on stocks such as Century Therapeutics, Atara Biotherapeutics, and Assembly Biosciences. According to TipRanks, Syed has an average return of -1.0% and a 42.91% success rate on recommended stocks.
Currently, the analyst consensus on Vaxcyte is a Strong Buy with an average price target of $116.00, which is a 125.51% upside from current levels. In a report released on June 3, Guggenheim also maintained a Buy rating on the stock with a $116.00 price target.
Based on Vaxcyte’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $320.62 million. In comparison, last year the company had a GAAP net loss of $140.72 million
